SciELO - Scientific Electronic Library Online

 
vol.15 issue3Treatment of refractory chest angina with spinal electrical stimulator: literature reviewUpdate article for continuous education: Tetralogy of Fallot author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista Colombiana de Cardiología

Print version ISSN 0120-5633

Abstract

BARON O, Ana M  and  BARON C, Alberto. Cardiovascular involvement in Fabry disease. Rev. Col. Cardiol. [online]. 2008, vol.15, n.3, pp.134-138. ISSN 0120-5633.

Fabry disease is a genetic condition that causes lysosomal storage of products like glotriaosylceramide, neural glycosphingolipids and diagalactosylceramide, as a consequence of alpha-galactosidase A enzyme deficiency. Clinical manifestations begin in childhood, but they are subtle, and can mimic other pathologies, delaying the diagnosis until the second or third decade of life, when the disease is in an advanced stage. In adults the most affected organs are heart, kidneys and brain. Cardiac involvement is one of the most important causes of morbidity and mortality. Deposits of these molecules occur in every component of the heart, leading to hypertrophy, ischemia and myocardial remodeling. Nowadays there is specific enzyme replacement therapy with recombinant agalacidase A and B that decreases lysosomal deposits and modifies the course of the disease. We recommend an increment in the disease surveillance in order to achieve early detection and treatment.

Keywords : Fabry disease; lysosomal storage disease; hypertrophic cardiomyopathy; myocardial ischemia.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License